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No-reﬂow after percutaneous coronary intervention (PCI) has
een shown to predict larger myocardial infarct size and as a
esult, poor clinical outcomes. Thus, accurately detecting high-risk
esions of no-reﬂow phenomenon is warranted for interventional
ardiologists. No-reﬂow phenomenon is caused by multiple fac-
ors including endothelial dysfunction, myocyte edema, neutrophil
nﬁltration, microvascular spasm, oxygen-free radicals, and distal
mbolization of plaque and/or thrombus at culprit coronary lesion.
mong these factors, distal embolization of the contents of the
laque and/or thrombus might be prevented, therefore several dis-
al protection devices have been developed, and the interventional
ardiologists realized their clinical usefulness. However, there are
ew articles to elucidate the usefulness of the distal protection
evices. Incidence of no-reﬂow phenomenon is around 11–15%
fter PCI in acute coronary syndrome (ACS) [1,2]. Namely, because
he majority of patients do not require distal protection devices,
e cannot prove the effectiveness on the premise to use distal
rotection devices for all cases. If a randomized clinical trial were
o be conducted in patients who are at high risk of no-reﬂow
henomenon during PCI, the effectiveness of the distal protection
evices might be demonstrated. Based on this way  of thinking,
arious researches to investigate the predictors of no-reﬂow phe-
omenon using imaging modalities have been actively carried out.
In imaging modality used for predictive factor identiﬁcation of
o-reﬂow phenomenon, at ﬁrst, intravascular ultrasound (IVUS)
as the main constituent. Tanaka et al. showed that lipid pool-
ike image and large vessels were independent predictive factors
f no-reﬂow phenomenon after reperfusion of acute myocardial
nfarction (AMI) [3]. Watanabe et al. also showed that positively
emodeled vessels with lipid-rich plaques as characterized by IVUS
efore PCI predicted the occurrence of angiographic no-reﬂow [4].
heir observation suggested that large amounts of plaque and
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Open access under CC BY-NC-ND licenlipid-like images estimated by IVUS might be associated with the
occurrence of no-reﬂow phenomenon. However, lipid-like image
estimated by IVUS is not a major predictor of no-reﬂow phe-
nomenon in the real-world clinical setting, whereas, attenuated
plaque is an important predictor in clinical practice. Okura et al.
showed attenuated plaques might be related to a transient deteri-
oration in coronary ﬂow and result in larger infarct size and higher
incidence of fatal arrhythmia following PCI in patients with ACS [5].
Yamada et al. evaluated the histological characteristics of plaques
and revealed that attenuated plaques contained more ﬁbrofatty tis-
sue and necrotic core compared to non-attenuated plaques [6]. In
this way, several studies have been done, however they were unfor-
tunately not enough to be convincing because of small sample size.
Although it is not an article to make speciﬁc mention of no-reﬂow
phenomenon, Mehran et al. investigated 2256 cases by using IVUS
and demonstrated that extensive atherosclerotic plaque burden
both at the lesion and reference segment were independent predic-
tors of creatine kinase-MB elevation after PCI [7]. Wu  et al. analyzed
clinical, angiographic, and IVUS data from 364 patients (n = 364
infarct-related arteries) enrolled in the randomized HORIZONS-
AMI trial. They concluded that the amount of attenuated plaque
strongly correlated with no-reﬂow phenomenon [8]. In the clinical
setting, many Japanese interventional cardiologists determine the
indication of distal protection devices according to plaque volume
and presence of attenuated plaque. This judgment is simple and
quick, therefore this decision-making manner is widely accepted.
Recently, Shibuya et al. reported that although tissue characteriza-
tion of integrated backscatter (IB)-IVUS might provide additional
information for distal embolization, plaque volume was the only
signiﬁcant predictor of distal embolization during PCI [9]. As seen
from the above, IVUS derived-plaque volume is an important factor
to predict no-reﬂow after PCI.
On the other hand, optical coherence tomography (OCT) is a
new imaging modality with unrivaled high resolution of 10–20 m.
OCT has higher image resolution than IVUS and is superior in the
evaluation of the plaque contents including calciﬁcation, throm-
bus, lipid pool, and thin-cap ﬁbroatheroma (TCFA). However, OCT
has several limitations. Because of the limited penetration depth
of OCT (2 mm),  plaque volume or arterial remodeling of atheroma-
tous plaques cannot be estimated by OCT. In addition, the presence
of thrombus, especially red thrombus, at the ACS lesion severely
affects imaging analysis by OCT. Because exclusion of the blood is
necessary, it may  not be applicable for assessment of ostial coro-
nary disease, severe stenotic lesions, and total occluded lesions.
There are few articles that investigated the predictors of no-reﬂow
se.
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fter PCI by using OCT. Tanaka et al. revealed as follows: TCFA were
ore frequently observed in the no-reﬂow group than in the reﬂow
roup (50% vs. 16%, p < 0.005). The frequency of the no-reﬂow phe-
omenon increases according to the size of the lipid arc in the
ulprit plaque. A multivariable logistic regression model revealed
hat lipid arc alone was an independent predictor of no-reﬂow phe-
omenon in non-ST-segment elevation acute coronary syndrome
10]. Ozaki et al. also showed that TCFA was a high-risk plaque
or microvascular obstruction after PCI in patients with ACS. Their
onclusions suggested OCT-derived TCFA was an important predic-
or of no-reﬂow phenomenon [11]. As just described, IVUS-derived
laque volume is an important factor to predict no-reﬂow after
CI. It is necessary to quote the paper of Miyamoto et al. [12],
n order to understand this discrepancy. They revealed that the
CT-derived TCFA had larger plaque burden and positive remod-
ling with predominant lipid component and less ﬁbrous plaque
ssessed by IB-IVUS. In this way, OCT-derived TCFA is a surrogate
arker of large plaque burden.
Ikenaga et al. [13] investigated AMI  patients using OCT and con-
luded that length of lipid pool was associated with microvascular
o-reﬂow after primary PCI. Because plaque contents of culprit
esion in AMI include thrombus, evaluation by OCT is difﬁcult
ue to the nature of this imaging modality. Thrombus hides
he microarchitecture of plaque. Therefore, it might be possible
hat some TCFAs were misdiagnosed as non-TCFA. The authors
valuated longitudinal extent of lipid by multi cross-sectional OCT
mages to prevent misdiagnosis. At this point, it was thought that
here was originality in this study. Unfortunately in the present
tudy, patients with large vessels or less than thrombolysis in
yocardial infarction grade 3 ﬂow were excluded. A further study
nrolling such patients who were excluded in the present study
s needed to make this way of detection more convincing in
eal-world clinical practice.
Despite several limitations of OCT, this innovative tool has var-
ous potentials in our ﬁeld. Future studies using OCT might help
s to predict no-reﬂow phenomenon by more precise imaging of
ntravascular pathophysiology and might eventually improve clin-
cal outcomes of patients treated with PCI. I strongly hope that OCT
rovides new knowledge into interventional cardiology.
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